May 24, 2018 PR-M05-18-NI-093
EVANSTON, Ill., May 22, 2018 /PRNewswire/ -- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator. Aptinyx discovered AGN-241751 utilizing its proprietary chemistry platform and the compound was selected for further development by Allergan under its ongoing research collaboration with Aptinyx.
"Through our productive research collaboration with Aptinyx and parallel development of rapastinel, we have gained important insights into NMDA receptor modulation as a potential therapeutic approach for depression," said C. David Nicholson, Ph.D., chief R&D officer at Allergan. "We plan to advance AGN-241751 for the treatment of MDD and believe its pharmacological profile will enable it to become an oral complement to rapastinel, further bolstering our pipeline of therapeutics addressing areas of significant unmet medical need."
"Our research collaboration with Allergan has been fruitful for both parties and we are pleased our collaboration partner has elected to option and continue clinical development of AGN-241751 to augment its CNS portfolio," said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx. "The exercise of this option underscores the therapeutic potential of molecules generated from our discovery platform, which modulate NMDA receptors in a novel and differentiated way and may significantly improve the lives of patients suffering from various neurologic disorders."
Aptinyx and Allergan entered into their research collaboration to discover and characterize novel small-molecule NMDA receptor modulators using Aptinyx's proprietary chemistry platform. Under the collaboration, Allergan funds a portion of the collaboration costs and receives options to acquire a defined number of compounds for development and commercialization within a limited field of indications. None of the molecules Aptinyx has advanced into clinical development are subject to any Allergan option right.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.